Drug Trial Radar · NCT07100106
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
285
Planned (sponsor's estimate)
Start
Oct 7, 2025
Primary completion
Aug 31, 2028
Study completion Aug 31, 2028
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Roche (China) Holding Ltd.
- First posted
- Aug 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participants with locally advanced or metastatic ER+, HER2- breast cancer. The study consists of 2 phases: Phase Ib and Phase II. Phase Ib will evaluate the safety and pharmacokinetics (PK) of GDC-4198 alone and in combination with giredestrant. Phase II stage will compare the activity and safety of GDC-4198 and giredestrant with abemaciclib and giredestrant. Participants from Study RGT-419B\_01-101 (NCT05304962) who are experiencing clinical benefit with GDC-4198, as determined by the investigator, may enroll in this study and continue receiving GDC-4198 at their current dose level following closure of Study RGT-419B\_01-101.
Conditions
- Breast Cancer
Interventions
GDC-4198Drug
GDC-4198 will be administered orally.
GiredestrantDrug
Giredestrant will be administered orally.
AbemaciclibDrug
Abemaciclib will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: Incidence and Severity of Adverse Events (AEs)Time frame: Up to 36 months
- Phase Ib: Number of Participants With Dose-Limiting Toxicity (DLTs)Time frame: From Day 1 to Day 28 of Cycle 1 (1 cycle=28 days)
- Phase II: Progression-free Survival (PFS)Time frame: Up to 36 months
Locations
77 sites in 10 countries. Site status is shown where the registry gives one.
Clearview Cancer Institute - Huntsville
Huntsville, Alabama · Recruiting
University of Arizona Cancer Center
Tucson, Arizona · Recruiting
City of Hope
Duarte, California · Recruiting
City of Hope - Orange County Lennar Foundation Cancer Center
Irvine, California · Recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
University of California San Diego Medical Center
San Diego, California · Recruiting
UCSF Helen Diller Family CCC
San Francisco, California · Recruiting
University of Colorado Cancer Center
Aurora, Colorado · Recruiting
Sylvester Comprehensive Cancer Center
Miami, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Winship Cancer Institute of Emory University
Atlanta, Georgia · Recruiting
City of Hope® Cancer Center Chicago
Zion, Illinois · Recruiting
Barbara Ann Karmanos Cancer Institute
Detroit, Maine · Recruiting
Maryland Oncology Hematology - Annapolis
Annapolis, Maryland · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Washington University Siteman Cancer Center
St Louis, Missouri · Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Recruiting
New York Cancer & Blood Specialists
East Patchogue, New York · Recruiting
Montefiore Einstein Cancer Center
The Bronx, New York · Recruiting
Levine Cancer Institute
Charlotte, North Carolina · Recruiting
Novant Health Cancer Institute
Charlotte, North Carolina · Recruiting
Novant Health Oncology Specialists
Winston-Salem, North Carolina · Recruiting
Cleveland Clinic Mercy Hospital
Canton, Ohio · Recruiting
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio · Recruiting
Oncology Associates of Oregon, P.C
Eugene, Oregon · Recruiting
Penn State Health Milton S. Hershey Medical Center
Hershey, Pennsylvania · Recruiting
University of Pennsylvania - Abramson Cancer Center
Philadelphia, Pennsylvania · Recruiting
UPMC - Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Tennesse Oncology - Mt. Juliet Clinic
Mount Juliet, Tennessee · Recruiting
Vanderbilt Breast Center at One Hundred Oaks
Nashville, Tennessee · Recruiting
Texas Oncology (Worth) - USOR
Dallas, Texas · Recruiting
University of Utah Huntsman Cancer Institute
Salt Lake City, Utah · Recruiting
Virginia Oncology Associates (Norfolk) - USOR
Norfolk, Virginia · Recruiting
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia · Recruiting
Cancer Research SA
Adelaide, South Australia, Australia · Recruiting
Instituto Do Câncer Do Estado de São Paulo Octávio Frias de Oliveira - ICESP
São Paulo, Brazil · Recruiting
Beneficencia Portuguesa de Sao Paulo
São Paulo, Brazil · Recruiting
Hospital do Cancer de Pernambuco - HCP
Recife, Pernambuco, Brazil · Recruiting
ONCOSITE Centro de Pesquisa Clínica Em Oncologia
Ijuí, Rio Grande do Sul, Brazil · Recruiting
Irmandade Da Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.